FAQ
Frequently Asked Questions
If you have further questions, we would love to hear from you.
FAQ
TECHNOLOGY & APPROACH
Is it just a database?
The knowledge graph databse is the backbone and core to the solution, but the intelligence lies in how it’s interrogated. Deterministic sequencing produces compliant workstreams, discriminative logic classifies risks and generative AI produces expert-style commentary for specialist review. Together, these three layers transform raw data into actionable strategy.
Why now?
Two forces make PreQlinic essential right now: biotech teams are leaner than ever, outsourcing critical decisions, and AI has finally become powerful enough to support structured, evidence‑driven preclinical planning.
The industry should have had this years ago to cut waste and prevent avoidable missteps, but the tools weren’t ready. Now they are, and founders can’t afford the old inefficiencies.
FAQ
Reliability & Trust
AI is known to “hallucinate.” How do you stop that?
We constrain the system. The deterministic database sets hard boundaries; AI never invents milestones or costs outside validated ranges. Generative output is reviewable, flagged with sources, and designed to mimic expert commentary, not fabricate data.
Where does the knowledge come from?
The database is populated with regulator-anchored activities (ICH, FDA, EMA guidance), costings from real vendor quotes and workflows from lived preclinical experience. AI acts as the explainer and contextualiser, not the originator of science.
Who signs off?
Human oversight is core to the solution. AI accelerates and enforces structure, but reviews and challenges throughout the process are performed by our team of specialists, ensuring accountability and credibility.
FAQ
Value to Founders
What problem does this solve for biotech founders?
They waste up to 30% of budgets on duplicated, mis-sequenced, or regulator-rejected work. PreQlinic provides a single, accountable roadmap: clear milestones, costs, and investor-ready documentation.
How does it help non-technical founders?
It gives them the equivalent of a “virtual preclinical team” in a dashboard. Instead of chasing vendors and consultants piecemeal, they can see the full pathway with context for every decision.
Is this replacing CROs or consultants?
No, it orchestrates them. CROs still run studies, consultants still advise, but PreQlinic ensures the sequence, costs and outputs align with investor and regulator expectations.
FAQ
VALUE TO INVESTORS
Why would investors care?
Because poor execution is the number 1 reason biotech portfolios underperform. Investors want capital efficiency and de-risked milestones. PreQlini shows exactly where money goes and when value inflections are hit.
Can it really change portfolio economics?
Yes. Saving 20–30% per program compounds across a portfolio, not to mention programmes that are lost to overspend due to poor planning and investors lose faith. For a VC running 10 projects, that could free up from £5–10m in capital for the same stage progression.
How does this affect exit or licensing?
Regulator-ready documentation, transparent milestones, and predictable execution make assets more attractive for licensing or acquisition. That directly increases investor returns.
FAQ
MARKETING & POSITIONING
How big is the opportunity?
Who else is doing this?
Why will startups adopt this?
Because they’re under investor pressure to spend smarter, faster and with greater transparency. If one company in a cohort uses PreQlinic, the others risk looking sloppy by comparison.
FAQ
Team &
EXECUTION
How did you create this?
How do we know this isn’t “AI theatre”?
Because it already works. Input an indication and other parameters and the system generates a compliant roadmap with expert commentary. It’s not replacing scientists – it’s codifying their workflows, then using AI to structure and explain them.